Boehringer Ingelheim sued the federal government this afternoon in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies.

News Alert: Boehringer Ingelheim Sues HRSA in Defense of its 340B Contract Pharmacy Policy

Drug manufacturer Boehringer Ingelheim (BI) sued the federal government this afternoon in federal district court in Washington, D.C., in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies.

BI is the seventh manufacturer to file such a suit in defense of such a policy. The others are Astra Zeneca, Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics. An eighth manufacturer, Merck, on Sept. 1 began denying 340B discounts to hospitals that use contract pharmacies if the hospitals decline to provide their 340B contract pharmacy claims data. That policy also is eventually expected to lead to an eighth lawsuit by a drug manufacturer this year.

Drug manufacturer Boehringer Ingelheim (BI) sued the federal government this afternoon in federal district court in Washington, D.C., in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report